Skip to main content

Table 1 Characteristics of 12 randomised controlled trials of vitamin D supplements in populations with mean/median 25OHD < 25 nmol/L and clinical endpoints reported in abstract

From: Assessment of research waste part 2: wrong study populations- an exemplar of baseline vitamin D status of participants in trials of vitamin D supplementation

Study Clinical endpoint Endpoint type Study Size (N) 25OHD Assay Mean/Median 25OHD (SD) (nmol/L)a Result of Trialb
Brooke 1980 [44] Newborn outcomes Secondary 126 CBP 11 (1) Benefit
Chapuy 1994 [21] Fracture Primary 3270 CBP 20 (14) Benefit
Pfeifer 2000 [45] Risk of fall Secondary 148 Nicholls 19 (10) Neutral
Chapuy 2002 [46] Fracture Secondary 583 Incstar 22 (16) Neutral
Bischoff 2003 [47] Risk of fall Primary 122 Nicholls 23 (N/A) Neutral
Martineau 2011 [48] Tuberculosis sputum culture conversion Primary 126 LCMS/MS 21 (20) Neutral
Mosayebi 2011 [49] Multiple sclerosis disability score Primary 59 IDS 25 (7) Neutral
Amestejani 2012 [50] Atopic dermatitis Primary 60 Biosource 24 (5) Benefit
Schreuder 2012 [51] Pain Primary 84 Diasorin 20 (10) Neutral
Mozaffari-Khosravi 2013 [52] Depression score Primary 120 IDS 23 (N/A) Benefit
Hossain 2014 [53] Pregnancy outcomes Primary 200 Immunoassay 13 (N/A) Neutral
Bhan 2015 [54] All-cause mortality Secondary 105 LCMS/MS 22 (7) Neutral
  1. aAdjusted for assay- see text for details
  2. bBased on intention-to-treat analysis of all randomized participants for relevant endpoint. Assessed independently by two authors (MB, AG)
  3. Studies are listed in Additional file 1: Table S3 and the Additional file 1: Reference list
  4. Abbreviations: 25OHD 25-hydroxyvitamin D, SD standard deviation, N/A not available. CBP competitive binding protein; LCMS/MS- liquid chromatography tandem mass-spectrometry